Lucas Eduardo Botelho de Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lucas Eduardo Botelho de Souza has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
- Dimas Tadeu Covas
Department of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirao Preto 14040-900, SP, Brazil
13 shared publications - Eduardo Magalhaes Rego
Center for Cell-Based Therapy, University of São Paulo, Ribeirão Preto, Brazil; Laboratório de Investigação Médica (LIM) 31, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo.
10 shared publications - Fernando Queiroz Cunha
Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil; Center for Research in Inflammatory Diseases, CRID, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
9 shared publications Florêncio Figueiredo
9 shared publicationsJessica Temporal
9 shared publications- Jose Mauricio Mota
Instituto do Câncer do Estado de São Paulo, University of São Paulo, São Paulo, Brazil
9 shared publications
Latest Publications
- Open Access
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
CAR-T cells and other cellular therapies for solid tumors: Current challenges and emerging solutions
Recent advances in cancer immunotherapy have transformed adoptive cellular therapy, yielding remarkable clinical outcomes in hematological malignancies, whereas its efficacy in solid tumors remains severely limited by the immunosuppressive tumor microenvironment, antigen heterogeneity, and on-target/off-tumor toxicities. To address these challenges, this article reviewed the principal biological and translational barriers hindering solid tumor treatment, examining advanced modalities such as tumor-infiltrating lymphocytes, engineered T-cell receptors, and novel CAR expressing immune cells based on a comprehensive literature search across PubMed and Scopus.
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Open AccessCAR-T cells and other cellular therapies for solid tumors: Current challenges and emerging solutions
Recent advances in cancer immunotherapy have transformed adoptive cellular therapy, yielding remarkable clinical outcomes in hematological malignancies, whereas its efficacy in solid tumors remains severely limited by the immunosuppressive tumor microenvironment, antigen heterogeneity, and on-target/off-tumor toxicities. To address these challenges, this article reviewed the principal biological and translational barriers hindering solid tumor treatment, examining advanced modalities such as tumor-infiltrating lymphocytes, engineered T-cell receptors, and novel CAR expressing immune cells based on a comprehensive literature search across PubMed and Scopus.
- 25 July 2025
- Published by Elsevier in Journal of Proteomics
- Vol. 321, 105507
Proteomics analysis reveal early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer
- 25 July 2025
- Published by Elsevier in Journal of Proteomics
- Vol. 321, 105507
Proteomics analysis reveal early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer
- Open Access
- 4 October 2024
- Published by Springer Nature in Discover Applied Sciences
- Vol. 6 (10) , 1-21
Engineering synthetic and recombinant human lysosomal β-glucocerebrosidase for enzyme replacement therapy for Gaucher disease
- 4 October 2024
- Published by Springer Nature in Discover Applied Sciences
- Vol. 6 (10) , 1-21
Open AccessEngineering synthetic and recombinant human lysosomal β-glucocerebrosidase for enzyme replacement therapy for Gaucher disease
- Open Access
- 6 June 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (11) , 1320-1330
IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy
- 6 June 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (11) , 1320-1330
Open AccessIL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy
- 24 November 2023
- Published by Elsevier in Médecine du Sommeil
- Vol. 20 (4) , 248
Le sexe et le timing circadien modulent les toxicités hématologiques et hématopoïétiques de l’oxaliplatine
- 24 November 2023
- Published by Elsevier in Médecine du Sommeil
- Vol. 20 (4) , 248
Le sexe et le timing circadien modulent les toxicités hématologiques et hématopoïétiques de l’oxaliplatine
- Open Access
PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia
Detection of t(9;22), and consequent BCR::ABL1 fusion, is still a marker of worse prognosis for acute lymphoblastic leukemia (ALL), with resistance to tyrosine-kinase inhibitor therapy being a major obstacle in the clinical practice for this subset of patients. In this study, we investigated the effectiveness of targeting poly-ADP-ribose polymerase (PARP) in a model of BCR::ABL1 p190+ ALL, the most common isoform to afflict ALL patients, and demonstrated the use of experimental PARP inhibitor (PARPi), AZD2461, as a therapeutic option with cytotoxic capabilities similar to that of imatinib, the current gold standard in medical care. We characterized cytostatic profiles, induced cell death, and biomarker expression modulation utilizing cell models, also providing a comprehensive genome-wide analysis through an aCGH of the model used, and further validated PARP1 differential expression in samples of ALL p190+ patients from local healthcare institutions, as well as in larger cohorts of online and readily available datasets. Overall, we demonstrate the effectiveness of PARPi in the treatment of BCR::ABL1 p190+ ALL cell models and that PARP1 is differentially expressed in patient samples. We hope our findings help expand the characterization of molecular profiles in ALL settings and guide future investigations into novel biomarker detection and pharmacological choices in clinical practice.
Open AccessPARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia
Detection of t(9;22), and consequent BCR::ABL1 fusion, is still a marker of worse prognosis for acute lymphoblastic leukemia (ALL), with resistance to tyrosine-kinase inhibitor therapy being a major obstacle in the clinical practice for this subset of patients. In this study, we investigated the effectiveness of targeting poly-ADP-ribose polymerase (PARP) in a model of BCR::ABL1 p190+ ALL, the most common isoform to afflict ALL patients, and demonstrated the use of experimental PARP inhibitor (PARPi), AZD2461, as a therapeutic option with cytotoxic capabilities similar to that of imatinib, the current gold standard in medical care. We characterized cytostatic profiles, induced cell death, and biomarker expression modulation utilizing cell models, also providing a comprehensive genome-wide analysis through an aCGH of the model used, and further validated PARP1 differential expression in samples of ALL p190+ patients from local healthcare institutions, as well as in larger cohorts of online and readily available datasets. Overall, we demonstrate the effectiveness of PARPi in the treatment of BCR::ABL1 p190+ ALL cell models and that PARP1 is differentially expressed in patient samples. We hope our findings help expand the characterization of molecular profiles in ALL settings and guide future investigations into novel biomarker detection and pharmacological choices in clinical practice.
- 22 July 2023
- Published by Springer Nature
- Vol. 1429, 85-110
Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies
Our current genetic engineering capacity through synthetic biology and genome editing is the foundation of a revolution in biomedical science: the use of genetically programmed cells as therapeutics. The prime example of this paradigm is the adoptive transfer of genetically engineered T cells to express tumor-specific receptors, such as chimeric antigen receptors (CARs) or engineered T-cell receptors (TCR). This approach has led to unprecedented complete remission rates in patients with otherwise incurable hematological malignancies. However, this approach is still largely ineffective against solid tumors, which comprise the vast majority of neoplasms. Also, limitations associated with the autologous nature of this therapy and shared markers between cancer cells and T cells further restrict the access to these therapies. Here, we described how cutting-edge genome editing approaches have been applied to unlock the full potential of these revolutionary therapies, thereby increasing therapeutic efficacy and patient accessibility. Keywords Genome editing CRISPR/Cas9 TALEN CAR T cells Cell therapy
- 22 July 2023
- Published by Springer Nature
- Vol. 1429, 85-110
Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies
Our current genetic engineering capacity through synthetic biology and genome editing is the foundation of a revolution in biomedical science: the use of genetically programmed cells as therapeutics. The prime example of this paradigm is the adoptive transfer of genetically engineered T cells to express tumor-specific receptors, such as chimeric antigen receptors (CARs) or engineered T-cell receptors (TCR). This approach has led to unprecedented complete remission rates in patients with otherwise incurable hematological malignancies. However, this approach is still largely ineffective against solid tumors, which comprise the vast majority of neoplasms. Also, limitations associated with the autologous nature of this therapy and shared markers between cancer cells and T cells further restrict the access to these therapies. Here, we described how cutting-edge genome editing approaches have been applied to unlock the full potential of these revolutionary therapies, thereby increasing therapeutic efficacy and patient accessibility. Keywords Genome editing CRISPR/Cas9 TALEN CAR T cells Cell therapy
- 17 June 2023
- Published by Elsevier in Experimental Hematology
- Vol. 124, 22-35.e3
BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells
- 17 June 2023
- Published by Elsevier in Experimental Hematology
- Vol. 124, 22-35.e3
BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells
- Open Access
- 5 April 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (4) , 1098
Association between Immunophenotypic Parameters and Molecular Alterations in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a hematologic malignancy that occurs due to alterations such as genetic mutations, chromosomal translocations, or changes in molecular levels. These alterations can accumulate in stem cells and hematopoietic progenitors, leading to the development of AML, which has a prevalence of 80% of acute leukemias in the adult population. Recurrent cytogenetic abnormalities, in addition to mediating leukemogenesis onset, participate in its evolution and can be used as established diagnostic and prognostic markers. Most of these mutations confer resistance to the traditionally used treatments and, therefore, the aberrant protein products are also considered therapeutic targets. The surface antigens of a cell are characterized through immunophenotyping, which has the ability to identify and differentiate the degrees of maturation and the lineage of the target cell, whether benign or malignant. With this, we seek to establish a relationship according to the molecular aberrations and immunophenotypic alterations that cells with AML present.
- 5 April 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (4) , 1098
Open AccessAssociation between Immunophenotypic Parameters and Molecular Alterations in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a hematologic malignancy that occurs due to alterations such as genetic mutations, chromosomal translocations, or changes in molecular levels. These alterations can accumulate in stem cells and hematopoietic progenitors, leading to the development of AML, which has a prevalence of 80% of acute leukemias in the adult population. Recurrent cytogenetic abnormalities, in addition to mediating leukemogenesis onset, participate in its evolution and can be used as established diagnostic and prognostic markers. Most of these mutations confer resistance to the traditionally used treatments and, therefore, the aberrant protein products are also considered therapeutic targets. The surface antigens of a cell are characterized through immunophenotyping, which has the ability to identify and differentiate the degrees of maturation and the lineage of the target cell, whether benign or malignant. With this, we seek to establish a relationship according to the molecular aberrations and immunophenotypic alterations that cells with AML present.